Biochemistry
1 questionsShadow casting is used in -
NEET-PG 2015 - Biochemistry NEET-PG Practice Questions and MCQs
Question 871: Shadow casting is used in -
- A. Light microscopy
- B. Electron microscopy (Correct Answer)
- C. Fluorescence microscopy
- D. Phase contrast microscopy
Explanation: ***Electron microscopy*** - **Shadow casting** is a technique used in **electron microscopy** to enhance contrast and reveal the three-dimensional topography of small structures and molecules by depositing a thin film of heavy metal at an angle. - This process creates areas with more metal (which appears darker) and areas shielded from the metal deposition (appearing lighter, like a shadow), thereby outlining the specimen. *Light microscopy* - **Light microscopy** uses visible light to illuminate specimens and a system of lenses to magnify images, and it does not typically employ shadow casting techniques for contrast enhancement. - While various techniques like staining are used for contrast, the principle of creating shadows by metal deposition is not applicable to light interactions with the sample. *Fluorescence microscopy* - **Fluorescence microscopy** utilizes the property of some substances to emit light of a longer wavelength when excited by light of a shorter wavelength (fluorescence), and it relies on fluorochromes for visualization, not shadow casting. - This technique creates contrast based on specific labels or autofluorescence, highlighting particular structures without direct shadowing. *Phase contrast microscopy* - **Phase contrast microscopy** converts phase shifts in light passing through a transparent specimen into changes in amplitude (brightness), which are then visible as differences in image contrast, and it does not involve metal deposition or shadow casting. - This method is particularly useful for observing live, unstained biological samples by detecting optical path differences.
Community Medicine
9 questionsHuman, animal, fomite or objects from which infective organism enters the host is called?
What is the definition of a reservoir in the context of infectious diseases?
Which of the following is NOT one of Bradford Hill's criteria for causation?
What is the primary benefit of screening for diseases?
Multiphasic screening means-
What is a key benefit of Randomized Controlled Trials (RCTs) in clinical research?
Most commonly used blinding technique in epidemiological studies?
Which one of the following is NOT a utilization rate?
Which of the following statements is true regarding a combined prospective-retrospective study?
NEET-PG 2015 - Community Medicine NEET-PG Practice Questions and MCQs
Question 871: Human, animal, fomite or objects from which infective organism enters the host is called?
- A. Infective Reservoir
- B. Infective Carrier
- C. None of the above
- D. Source of infection (Correct Answer)
Explanation: ***Source of infection*** - The **source of infection** refers to the person, animal, object, or substance from which an infectious agent passes immediately to a host. - This can include humans, animals, fomites, or contaminated objects that directly transmit the infectious organism. - This is the proximate source from which the agent enters the host. *Infective Reservoir* - An **infective reservoir** is the long-term habitat where an infectious agent normally lives, grows, and multiplies. - The reservoir can be human, animal, plant, soil, or inanimate matter where the agent is normally found. - While a reservoir can be a source, the source is specifically the immediate point from which transmission occurs. *Infective Carrier* - An **infective carrier** is an infected person or animal that harbors a specific infectious agent without showing clinical symptoms but can transmit it to others. - A carrier is a type of source (when transmission occurs from them), but the term "source" is broader, encompassing inanimate objects and fomites as well. *None of the above* - This option is incorrect because **Source of infection** accurately describes the concept presented in the question.
Question 872: What is the definition of a reservoir in the context of infectious diseases?
- A. Person, animal or object from which infectious agent is transmitted to host
- B. Person, animal or substance in which infectious agent lives and multiplies (Correct Answer)
- C. Person or animal in which infectious agent causes a disease
- D. Person or animal that transmits the infectious agent mechanically
Explanation: ***Person, animal or substance in which infectious agent lives and multiplies*** - A **reservoir** is the natural habitat where an **infectious agent** normally lives and multiplies, and from which it can be transmitted to a susceptible host. - This definition emphasizes residence and replication, not necessarily direct transmission to a new host or causation of disease in the reservoir itself. - Examples include humans (e.g., typhoid carriers), animals (e.g., rodents for plague), and environmental sources (e.g., soil for tetanus). *Person, animal or object from which infectious agent is transmitted to host* - This option describes a **source of infection**, which can be a reservoir but isn't always. A source is where a host acquires the infection, but not necessarily where the pathogen multiplies. - An object (fomite) can be a source of infection, but it's rarely a reservoir because pathogens generally do not live and multiply there for extended periods. *Person or animal in which infectious agent causes a disease* - This describes a **diseased host** or a **case**, not necessarily a reservoir. A reservoir may or may not experience disease from the pathogen it harbors. - For example, a **carrier** can be a reservoir without showing symptoms of disease. *Person or animal that transmits the infectious agent mechanically* - This describes a **vector**, particularly a mechanical vector (e.g., flies carrying pathogens on their body). - Unlike a reservoir, a vector does not provide a habitat where the pathogen lives and multiplies; it merely transports it from one location to another.
Question 873: Which of the following is NOT one of Bradford Hill's criteria for causation?
- A. Consistency of association
- B. Specificity of association
- C. Strength of association
- D. Absence of temporal relationship (Correct Answer)
Explanation: ***Absence of temporal relationship*** - Bradford Hill's criteria include **temporality** (temporal relationship), which states that the cause must precede the effect in time. - The criterion is the **presence** of a temporal relationship, not its absence. - "Absence of temporal relationship" is therefore NOT one of Bradford Hill's criteria—it is the opposite of what the criterion requires. - This is the correct answer to this "NOT" question. *Strength of association* - This **IS** one of Bradford Hill's criteria. - It refers to the **magnitude of the association** between exposure and outcome (measured by relative risk, odds ratio, etc.). - A stronger association provides more evidence for causality. *Consistency of association* - This **IS** one of Bradford Hill's criteria. - It means the association is observed **repeatedly** across different studies, populations, settings, and times. - Consistent replication strengthens the causal argument. *Specificity of association* - This **IS** one of Bradford Hill's criteria. - It suggests that a specific exposure leads to a specific outcome with limited alternative explanations. - While supportive of causation, Hill noted this criterion is less essential as many exposures have multiple effects.
Question 874: What is the primary benefit of screening for diseases?
- A. Early detection of diseases (Correct Answer)
- B. Providing support for patients after diagnosis
- C. Identifying all potential cases of a disease
- D. Timely treatment of identified conditions
Explanation: ***Early detection of diseases*** - This is the **primary benefit** and defining purpose of **screening programs** in public health. - Screening identifies diseases in their **presymptomatic or early stage** when individuals are apparently healthy, allowing for intervention before clinical symptoms appear. - According to epidemiological principles, the goal of screening is to detect disease **earlier than it would be found through routine clinical practice**. - Early detection enables better prognosis through **lead time** and **length time bias** advantages. *Timely treatment of identified conditions* - While treatment is the **ultimate goal** of healthcare, it is not specific to screening—treatment occurs whether disease is found through screening or clinical presentation. - Treatment is the **consequence** of early detection, not the primary benefit of the screening process itself. - The unique value of screening lies in **detection**, not treatment per se. *Providing support for patients after diagnosis* - **Patient support** is an important aspect of healthcare but is not the purpose of screening programs. - This is **post-diagnostic care**, which follows after the screening process has identified cases. *Identifying all potential cases of a disease* - **Screening tests** cannot identify all cases due to inherent limitations in **sensitivity** and **specificity**. - Screening aims to identify a significant proportion of cases in a population, accepting that some will be missed (**false negatives**) and some healthy individuals may test positive (**false positives**).
Question 875: Multiphasic screening means-
- A. Application of two or more screening tests in combination at different geographical areas
- B. Application of separate screening tests for different diseases
- C. Application of two or more screening tests in combination at one time (Correct Answer)
- D. Application of two or more screening tests in combination at different times
Explanation: ***Application of two or more screening tests in combination at one time*** - **Multiphasic screening** involves performing several screening tests simultaneously during a single screening session. - This approach aims to detect multiple diseases or risk factors efficiently within a single visit or examination. *Application of two or more screening tests in combination at different times* - This describes repeated screening or sequential screening, where tests are administered over a period, not the immediate, combined approach of multiphasic screening. - **Multiphasic screening** specifically refers to the concurrent application of multiple tests, not their staggered use. *Application of two or more screening tests in combination at different geographical areas* - This concept relates more to large-scale public health programs or epidemiological studies across regions, rather than the definition of multiphasic screening itself. - Geographical variation is not a defining characteristic of multiphasic screening. *Application of separate screening tests for different diseases* - While multiphasic screening indeed uses separate tests for different diseases, the key aspect is their **simultaneous application** at one time to a single individual, which this option omits. - This option describes the general nature of screening for various conditions but misses the crucial element of combination and timing.
Question 876: What is a key benefit of Randomized Controlled Trials (RCTs) in clinical research?
- A. They can be conducted more quickly than other study types.
- B. They minimize selection bias. (Correct Answer)
- C. They are ideal for studying rare diseases.
- D. They are generally less expensive than other study types.
Explanation: ***They minimize selection bias.*** - **Randomization** in RCTs ensures that participants have an equal chance of being assigned to any of the treatment groups, thereby balancing potential **confounding factors** across groups. - This balance helps to ensure that any observed differences in outcomes between groups are more likely due to the intervention being studied rather than pre-existing differences among participants, thus minimizing **selection bias**. *They can be conducted more quickly than other study types.* - RCTs often require **extensive planning**, recruitment, and follow-up periods, making them one of the **most time-consuming** study designs. - The need for sufficient **power** to detect meaningful differences often translates into longer study durations. *They are ideal for studying rare diseases.* - Due to the requirement for **large sample sizes** to demonstrate statistical significance, RCTs are **not practical** for diseases with low prevalence. - Recruiting enough participants with a rare disease for an RCT can be extremely challenging and often **unfeasible**. *They are generally less expensive than other study types.* - RCTs are typically among the **most expensive** study designs because they involve extensive participant recruitment, intervention administration, data collection, and long-term follow-up. - The costs associated with staff, resources, and monitoring for ethical compliance contribute to their **high financial burden**.
Question 877: Most commonly used blinding technique in epidemiological studies?
- A. None of the options
- B. Single blinding
- C. Double blinding (Correct Answer)
- D. Triple blinding
Explanation: ***Double blinding*** - In **double blinding**, neither the **participants** nor the **researchers** administering the intervention and collecting data know who is in the treatment group versus the control group. - This method is widely used to prevent **observer bias** from the researchers and **participant bias** (e.g., placebo effect) from the subjects, thereby strengthening the study's internal validity. *Single blinding* - In **single blinding**, only the **participants** are unaware of their assignment to either the treatment or control group. - While it helps reduce participant bias, the **researchers' knowledge** of group assignments can still introduce **observer bias**, making it less rigorous than double blinding. *Triple blinding* - **Triple blinding** extends double blinding by ensuring that the **data analysts** are also unaware of the participant group assignments. - This technique further minimizes bias in the **interpretation and analysis of results**, but it is less commonly implemented due to its complexity and increased logistical challenges compared to double blinding. *None of the options* - This option is incorrect because **blinding techniques** are fundamental tools in epidemiological studies and clinical trials to ensure the objectivity and reliability of research findings. - **Blinding** helps eliminate conscious and unconscious biases that could otherwise influence study outcomes.
Question 878: Which one of the following is NOT a utilization rate?
- A. Population bed ratio (Correct Answer)
- B. Bed occupancy rate
- C. Bed turnover ratio
- D. Average length of stay
Explanation: ***Population bed ratio*** - The **population bed ratio** indicates the number of available beds per unit of population, reflecting healthcare **resource availability** rather than resource utilization. - It is a measure of healthcare capacity and access, not how intensively those beds are being used. *Bed occupancy rate* - The **bed occupancy rate** measures the proportion of available hospital beds that are occupied over a given period, directly indicating the **utilization** of bed resources. - A higher rate suggests more efficient use of beds, while a lower rate may indicate underutilization or excess capacity. *Bed turnover ratio* - The **bed turnover ratio** calculates the number of patients discharged per bed over a specific period, reflecting how frequently beds are being used and re-used. - It indicates the **efficiency** with which beds are being utilized and cleared for new patients. *Average length of stay* - The **average length of stay (ALOS)** represents the average number of days a patient remains hospitalized, which directly relates to the **duration of bed utilization** per patient. - A shorter ALOS can indicate more efficient use of beds, while a longer ALOS may suggest higher resource consumption per patient.
Question 879: Which of the following statements is true regarding a combined prospective-retrospective study?
- A. Only prospective follow-up from current time point
- B. Retrospective identification of cohort followed by prospective follow-up (Correct Answer)
- C. Cross-sectional assessment at a single time point
- D. Only retrospective data collection from past records
Explanation: ***Retrospective identification of cohort followed by prospective follow-up*** - This correctly describes a **combined prospective-retrospective study** (also called an **ambispective or historical prospective study**) - The study begins by **retrospectively identifying a cohort** from past records (e.g., employees exposed to a chemical 10 years ago) - **Past exposure data is collected retrospectively** from existing records - The identified cohort is then **followed forward prospectively** from the current time point to observe future outcomes - This approach combines the **efficiency of retrospective data collection** with the **rigor of prospective follow-up** *Only prospective follow-up from current time point* - The word **"only"** is the critical error - it excludes the retrospective component - This describes a **purely prospective cohort study**, not a combined study - A combined study must include **both retrospective and prospective elements** *Only retrospective data collection from past records* - This describes a **purely retrospective study** (case-control or retrospective cohort) - It lacks the prospective follow-up component essential to a combined study *Cross-sectional assessment at a single time point* - This defines a **cross-sectional study** that provides a snapshot at one moment - It involves neither retrospective cohort identification nor prospective follow-up